Peginterferon therapy in children with chronic Hepatitis C: A nationwide, multicenter study in Japan, 2004-2013

Journal of Pediatric Gastroenterology and Nutrition

Volumn 63, Issue 1, 2016, Pages 88-93

  Suzuki, Mitsuyoshi ^a   Tajiri, Hitoshi ^b   Tanaka, Yasuhito ^c   Takano, Tomoko ^b   Miyoshi, Yoko ^d   Murakami, Jun ^e   Shimizu, Toshiaki ^a   Brooks, Stephen ^f  

^a JUNTENDO UNIVERSITY   (Japan)

^b OSAKA GENERAL MEDICAL CENTER   (Japan)

^c NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^d OSAKA UNIVERSITY   (Japan)

^e TOTTORI UNIVERSITY   (Japan)

^f UNIVERSITY AT BUFFALO   (United States)

Author keywords

Asian population; HCV genotype; IL28B polymorphisms; ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEMOGLOBIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; ALLELE; CHRONIC HEPATITIS C; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEPRESSION; DNA POLYMORPHISM; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; FEVER; FLU LIKE SYNDROME; GENE; GENOTYPE; GROUPS BY AGE; HAIR LOSS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPERTRANSAMINASEMIA; IL28B GENE; JAPAN; LETHARGY; LEUKOPENIA; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; CHILD HEALTH CARE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; GENETICS; MEDICAL RECORD; MORTALITY; MULTICENTER STUDY; PRESCHOOL CHILD; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADOLESCENT; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; CHILD HEALTH SERVICES; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; JAPAN; MALE; MEDICAL RECORDS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84955606479     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000001120     Document Type: Review

References (30)

1. El-Shabrawi MH, Kamal NM. Burden of pediatric hepatitis C. World J Gastroenterol 2013; 19: 7880-8.
2. Liakina V, Hamid S, Tanaka J, et al. Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 3. J Viral Hepat 2015; 22(suppl 4): 4-20.
3. Tanaka J, Koyama T, Mizui M, et al. Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age- and areaspecific prevalence on the national scale. Intervirology 2011; 54: 185-95.
4. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 22 2001; 358: 958-65.
5. Suzuki F. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2014 in Japan [in Japanese]. Nihon Rinsho 2015; 73: 215-20.
6. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLDIDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62: 932-54.
7. European Association for the Study of the Liver. Electronic address eee. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015; 63: 199-236.
8. Mack CL, Gonzalez-Peralta RP, Gupta N, et al. NASPGHAN practice guidelines: diagnosis and management of hepatitis C infection in infants, children, and adolescents. J Pediatr Gastroenterol Nutr 2012; 54: 838-55.
9. Druyts E, Thorlund K, Wu P, et al. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and metaanalysis. Clin Infect Dis 2013; 56: 961-7.
10. Schwarz KB, Molleston JP, Jonas MM, et al. Children treated with pegylated interferon alfa-2a-ribavirin for chronic hepatitis C. J Pediatr Gastroenterol Nutr 2016; 62: 93-6.
11. Tajiri H, Tanaka Y, Takano T, et al. Association of IL28B polymorphisms with virological response to peginterferon and ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatol Res 2014; 44: E38-44.
12. Tajiri H, Inui A, Kiyohara Y, et al. Peginterferon alpha-2b and ribavirin for the treatment of chronic hepatitis C in Japanese pediatric and young adult patients: a survey of the Japan Society of Pediatric Hepatology. Eur J Gastroenterol Hepatol 2009; 21: 1256-60.
13. Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962-73.
14. Takahara T, Furui K, Yata Y, et al. Dual expression of matrix metalloproteinase-2 and membrane-type 1-matrix metalloproteinase in fibrotic human livers. Hepatology 1997; 26: 1521-9.
15. Hiramine S, Sugiyama M, Furusyo N, et al. A thymine-Adenine dinucleotide repeat polymorphism near IL28B is associated with spontaneous clearance of hepatitis C virus. J Gastroenterol 2015; 50: 1069-1077.
16. Khaderi S, Shepherd R, Goss JA, Leung DH. Hepatitis C in the pediatric population: transmission, natural history, treatment and liver transplantation. World J Gastroenterol 2014; 20: 11281-6.
17. Wirth S, Pieper-Boustani H, Lang T, et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005; 41: 1013-8.
18. Schwarz KB, Gonzalez-Peralta RP, Murray KF, et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 2011; 140: 450-8.
19. Wirth S, Ribes-Koninckx C, Calzado MA, et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 2010; 52: 501-7.
20. Sokal EM, Bourgois A, Stephenne X, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol 2010; 52: 827-31.
21. Hayashida A, Inaba N, Oshima K, et al. Re-evaluation of the true rate of hepatitis C virus mother-to-child transmission and its novel risk factors based on our two prospective studies. J Obstet Gynaecol Res 2007; 33: 417-22.
22. Indolfi G, Resti M. Perinatal transmission of hepatitis C virus infection. J Med Virol 2009; 81: 836-43.
23. Murakami J, Nagata I, Iitsuka T, et al. Risk factors for mother-to-child transmission of hepatitis C virus: maternal high viral load and fetal exposure in the birth canal. Hepatol Res 2012; 42: 648-57.
24. Mast EE, Hwang LY, Seto DS, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCVinfection acquired in infancy. J Infect Dis 2005; 192: 1880-9.
25. Indolfi G, Bartolini E, Casavola D, et al. Chronic hepatitis C virus infection in children and adolescents: epidemiology, natural history, and assessment of the safety and efficacy of combination therapy. Adolesc Health Med Ther 2010; 1: 115-28.
26. Tsunoda T, Inui A, Kawamoto M, et al. Effects of pegylated interferonalpha-2a monotherapy on growth in Japanese children with chronic hepatitis C. Hepatol Res 2014; 44: 251-8.
27. Schwarz KB, Mohan P, Narkewicz MR, et al. Safety, efficacy and pharmacokinetics of peginterferon alpha2a (40 kd) in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2006; 43: 499-505.
28. Tsunoda T, Inui A, Etani Y, et al. Efficacy of pegylated interferonalpha2a monotherapy in Japanese children with chronic hepatitis C. Hepatol Res 2011; 41: 399-404.
29. Shiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007; 132: 103-12.
30. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.